Pharmaceutical R&D is racing ahead of our health system's ability to adjust payment models, but innovative concepts are finally emerging.

The drug pricing debate in DC has intensified, and the pharmaceutical industry has become the prime target of bipartisan outrage.

The drug-price watchdog ICER just issued a "Report on Unsupported Price Increases". The 'study' made the headlines, but it is problematic.

This analysis outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make the industry.

5 observations as to where we are today, and what might lie ahead for Blockchain in Pharmaceutical Market Access.